Akebia posts wider-than-expected Q4 net loss as higher expenses hurt

Akebia Therapeutics

26/02/2026 12:14

Overview

Biopharmaceutical company's Q4 net income and operating income missed analyst expectations

Full-year net product revenues rose 49% over 2024, driven by Vafseo sales

Company expects significant Vafseo revenue growth in 2026 through expanded access

Outlook

Akebia expects significant Vafseo revenue growth in 2026 through expanded access and improved adherence

Company plans Phase 2 trial for AKB-097 in rare kidney diseases starting 2H 2026

Akebia expects Auryxia revenues to decrease in 2026 due to expanding generic competition

Result Drivers

EXPANDED ACCESS - Akebia expects significant Vafseo revenue growth in 2026 through expanded access to therapy at dialysis organizations, new patient starts, and improved adherence rates

IMPROVED ADHERENCE - Improved patient adherence rates for Vafseo attributed to observed dosing protocols at dialysis centers

PIPELINE ADVANCEMENT - Enrollment underway for praliciguat Phase 2 trial in FSGS and AKB-097 Phase 2 trial planned for 2H 2026

Company press release: ID:nGNX3s05qs

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Net Income
Miss
-$12.24 mln
-$7.67 mln (3 Analysts)
Q4 Operating Income
Miss
-$8.55 mln
-$5.36 mln (4 Analysts)
Q4 Operating Expenses
$53.64 mln


Analyst Coverage

The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy."

Wall Street's median 12-month price target for Akebia Therapeutics Inc is $4.00, about 230.6% above its February 25 closing price of $1.21

The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 16 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)